StockData
Immuneering Corp logo

Immuneering Corp (IMRX) stock

IMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 8/30
$3.52−0.19 (-5.12%)

Close on Nov 16, 2026Market cap $227.97MP/E –Yield –

Immuneering ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Immuneering's ebitda for the twelve months ending Sep 30, 2026 was -$73.55M. For fiscal 2025 it was -$59.05M.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$59.05M–
FY2024Dec 31, 2024-$63.72M–
FY2023Dec 31, 2023-$58.09M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$25.70M–
Q2 FY2026Jun 30, 2026-$18.92M–
Q1 FY2026Mar 31, 2026-$15.25M–
Q4 FY2025Dec 31, 2025-$13.68M–
Q3 FY2025Sep 30, 2025-$15.30M–
Q2 FY2025Jun 30, 2025-$14.67M–
Q1 FY2025Mar 31, 2025-$15.40M–
Q4 FY2024Dec 31, 2024-$18.47M–
Q3 FY2024Sep 30, 2024-$15.18M–
Q2 FY2024Jun 30, 2024-$14.82M–
Q1 FY2024Mar 31, 2024-$15.24M–
Q4 FY2023Dec 31, 2023-$16.21M–
Q3 FY2023Sep 30, 2023-$13.85M–
Q2 FY2023Jun 30, 2023-$13.43M–
Q1 FY2023Mar 31, 2023-$14.60M–
Q3 FY2022Sep 30, 2022-$13.12M–
Q2 FY2022Jun 30, 2022-$11.59M–

More Immuneering figures

See a number that looks wrong?